Information Provided By: 
Fly News Breaks for October 19, 2015
BLUE, ADRO
Oct 19, 2015 | 16:15 EDT
Oppenheimer analyst Wendy Lam started shares of Aduro Biotech (ADRO) with an Outperform rating and $30 price target. The company has two proprietary first-in-class immunotherapy platforms that offer broad utility across multiple cancer types, Lam tells investors in a research note. The analyst also initiated after today's close shares of bluebird bio (BLUE) with an Outperform rating and $162 price target.
News For ADRO;BLUE From the Last 2 Days
There are no results for your query ADRO;BLUE
